Claims for Patent: 8,835,646

Summary for Patent: 8,835,646

Title:	Organic compounds
Abstract:	The present invention provides a compound of formula I: ##STR00001## Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.
Inventor(s):	Ksander; Gary Michael (Amherst, NH), Meredith; Erik (Hudson, MA), Monovich; Lauren (Belmont, MA), Papillon; Julien (Somerville, MA), Firooznia; Fariborz (Florham Park, NJ), Hu; Qi-Ying (Needham, MA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/927,514
Patent Claims:	1. A compound of formula (II) ##STR00250## wherein R is selected from the group consisting of: hydrogen, (C.sub.1-C.sub.7) alkyl, and (C.sub.2-C.sub.7) alkenyl; R.sub.1 is selected from F, Cl, Br, I and H.sub.2N--; R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are selected independently from the group consisting of: hydrogen, (C.sub.2-C.sub.7) alkenyl, (C.sub.1-C.sub.7) alkyl, (C.sub.3-C.sub.8) cycloalkyl, F, Cl, Br, I, cyano, nitro, H.sub.2N--, (C.sub.1-C.sub.7) haloalkyl, and (C.sub.1-C.sub.7) alkoxy; R.sub.6 and R.sub.7 are hydrogen; or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers. 2. The compound of claim 1, wherein R is hydrogen; R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are independently selected from hydrogen, F, Cl, Br, I, cyano, --NH.sub.2, or (C.sub.1-C.sub.4) alkoxy; or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers. 3. The compound of claim 1, wherein R is hydrogen R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are independently selected from hydrogen, halo, F, Cl, Br, I, cyano or (C.sub.1-C.sub.4) alkyl; or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers. 4. A compound according to claim 1 selected from the group consisting of 4-(R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile; 3-Bromo-4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-benzonitrile; 3-Chloro-4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-benzonitrile; and 3-Amino-4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-benzonitrile; or a pharmaceutically acceptable salt thereof. 5. A compound according to claim 1 which is a enantiomeric mixture of isomers selected from 4-(R)-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile and 4-(S)-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitr- ile in free form or as a pharmaceutically acceptable salt thereof formed with a suitable inorganic acid selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid and hydrohalic acid. 6. The R enantiomer of a compound of claim 1 which has the formula ##STR00251## as a pharmaceutically acceptable salt formed with a suitable inorganic acid selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid and hydrohalic acid. 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers for use in a method of treating cancer. 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, for use in a method of treating-an estrogen-dependent disorder or disease selected from the group consisting of: gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer, Cushings disease and fibrocystic mastopathy.